BIOCRYST PHARMACEUTICALS INC
Company Stats
- Market Cap
- $2.1B
- as of Sep 30, 2026
- Shares Outstanding
- 255.5M
- Free Float
- 96.1%
Income Statement
- Revenue
- $874.8M
- Operating Income
- $341.0M
- Net Income
- $263.9M
- EBITDA
- $342.4M
- Revenue Growth, 3Y
- 47.8%
- FCF Margin, 3Y Avg
- -0.6%
- FCF Margin, Worst Year
- -29.4%
Cash Flow
- Free Cash Flow
- $344.9M
- FCF Yield
- 16.2%
- Owner FCF Yield
- 12.2%
Balance Sheet
- Cash & Equivalents
- $89.7M
Returns & Capital
- SBC, 3Y Avg
- $68.7M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $874.8M | $344.9M | 39.4% |
| FY2024 | $450.7M | -$53.1M | -11.8% |
| FY2023 | $331.4M | -$97.3M | -29.4% |
| FY2022 | $270.8M | -$163.2M | -60.3% |
| FY2021 | $157.2M | -$144.5M | -92.0% |
Annual filing data through FY ended December 31, 2025; shares and float as of October 24, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges